This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Imaging			
^{99m} Tc-based prostate-specific membrane antigen (PSMA)-targeted radioimaging agents	<p>Two studies in mice and in cell culture identified radioimaging compounds that could be useful for the early detection and treatment of prostate cancer. A ^{99m}Tc-based compound targeting PSMA accumulated primarily in PSMA-positive kidney and prostate cancer cells. In PSMA-positive human prostate cancer xenograft mice, a construct of the radioimaging compound combined with a derivative of microtubule inhibitor tubulysin B produced tumor regression with no toxicity-related weight loss. Next steps include evaluating the compounds as imaging agents in a clinical trial.</p> <p>SciBX 2(16); doi:10.1038/scibx.2009.684 Published online April 23, 2009</p>	<p>Multiple patent applications filed covering use of PSMA-targeted imaging and therapeutic agents in solid tumors, including prostate cancer; available for licensing from the Purdue Research Foundation Office of Technology</p>	<p>Kularatne, S.A. <i>et al. Mol. Pharm.</i>; published online April 11, 2009; doi:10.1021/mp9000712 Kularatne, S.A. <i>et al. Mol. Pharm.</i>; published online April 12, 2009; doi:10.1021/mp900069d Contact: Philip S. Low, Purdue University, West Lafayette, Ind. e-mail: plow@purdue.edu</p>